sALT629 

sALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC₅₀ = 1.5 μM). sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid (HY-10394) and Sutezolid (HY-10392). sALT629 can be used for the research of tuberculosis^[1].

sALT629 (0.96-12.5 μM) exhibits inhibitory activity against Mtb cultured on four carbon sources (acetate, butyrate, cholesterol, glucose), with an EC₅₀ of 1.5 μM against intramacrophage Mtb, an MIC of 0.8-1.7 μM against multidrug-resistant (MDR), extensively drug-resistant (XDR), and single-drug-resistant Mtb strains, and activity against slow-replicating and nonreplicating Mtb^[1].
sALT629 (1.7-13.6 μM; 7 days) shows dose-dependent bactericidal activity against Mtb in 7H12 cholesterol media^[1].
sALT629 (20 μM; 7 days) reduces CFU by approximately 1.5-log in the Hu-Coates 100-day dormancy model and by 0.5-log in Loebel's nutritionally deprived model^[1].
sALT629 (>40 μM) shows no significant cytotoxicity against HEK293T and HepG2 cells, with a SI greater than 23^[1].
sALT629 exhibits synergistic activity when combined with oxazolidinone drugs (Linezolid (HY-10394), Sutezolid (HY-10392)) with an FIC of 0.5, additive effects with drugs such as TBD11, TBA-7371 (HY-19750), and Q203 (HY-101040) (FIC=0.63-1.0), and no significant interaction with Isoniazid (HY-B0329) and other agents (FIC>1.0)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

sALT629 (30-100 mg/kg BID, or 200 mg/kg QD, p.o., for 4 consecutive days) exhibits no significant toxicity in CD-1 mice, with no body weight loss or abnormalities in clinical chemistry and hematology indices^[1].
sALT629 (100 mg/kg BID, or 200 mg/kg QD, p.o., for 4 consecutive days) shows plasma concentrations remaining above EC₅₀ for over 24 hours, and lung tissue exposure exceeds EC₅₀^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

275.31

C₁₃H₁₇N₅O₂

484026-63-3

O=C(CN1N=NC(C2=CC=C(C=C2)OCC(C)C)=N1)N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang B, et al. Design, Synthesis, and Biological Evaluation of Tetrazol-2-yl-acetamides as Novel Antitubercular Agents. ACS Med Chem Lett. 2025 Nov 21;16(12):2444-2453.  [Content Brief]